EA201991643A1 - Человеческие антитела к токсину гемолизину а s.aureus - Google Patents

Человеческие антитела к токсину гемолизину а s.aureus

Info

Publication number
EA201991643A1
EA201991643A1 EA201991643A EA201991643A EA201991643A1 EA 201991643 A1 EA201991643 A1 EA 201991643A1 EA 201991643 A EA201991643 A EA 201991643A EA 201991643 A EA201991643 A EA 201991643A EA 201991643 A1 EA201991643 A1 EA 201991643A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
aureus
toxin
hemolysin
human antibodies
Prior art date
Application number
EA201991643A
Other languages
English (en)
Inventor
Алида Коппи
Питер Мэйсон
Уилльям Олсон
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201991643A1 publication Critical patent/EA201991643A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении предложены антитела, которые связываются с токсином гемолизином A Staphylococcus aureus, и к способам их применения. В соответствии с определенными вариантами осуществления антитела представляют собой полностью человеческие антитела, которые связываются с гемолизином A. Антитела по настоящему изобретению пригодны для ингибирования или нейтрализации активности гемолизина A, таким образом обеспечивая средства профилактики или лечения заболевания или нарушения, связанного с гемолизином A, такого как инфекция, вызываемая S.aureus. В некоторых вариантах осуществления антитела по настоящему изобретению используют в лечении по меньшей мере одного симптома или осложнения инфекции, вызываемой S.aureus.
EA201991643A 2017-01-03 2018-01-02 Человеческие антитела к токсину гемолизину а s.aureus EA201991643A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762441786P 2017-01-03 2017-01-03
PCT/US2018/012044 WO2018128973A1 (en) 2017-01-03 2018-01-02 Human antibodies to s. aureus hemolysin a toxin

Publications (1)

Publication Number Publication Date
EA201991643A1 true EA201991643A1 (ru) 2020-01-20

Family

ID=61054509

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991643A EA201991643A1 (ru) 2017-01-03 2018-01-02 Человеческие антитела к токсину гемолизину а s.aureus

Country Status (18)

Country Link
US (3) US10463748B2 (ru)
EP (1) EP3565835A1 (ru)
JP (2) JP2020504759A (ru)
KR (1) KR20190101435A (ru)
CN (1) CN110167960B (ru)
AR (1) AR110719A1 (ru)
AU (1) AU2018206531A1 (ru)
BR (1) BR112019013375A2 (ru)
CA (1) CA3048989A1 (ru)
CL (1) CL2019001836A1 (ru)
CO (1) CO2019006902A2 (ru)
EA (1) EA201991643A1 (ru)
IL (1) IL267600A (ru)
MA (1) MA47202A (ru)
MX (1) MX2019007784A (ru)
PH (1) PH12019501425A1 (ru)
TW (2) TW202311284A (ru)
WO (1) WO2018128973A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
WO2020106461A2 (en) * 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
CN109400704B (zh) * 2018-11-14 2020-07-21 珠海泰诺麦博生物技术有限公司 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用
US12024556B2 (en) * 2018-11-21 2024-07-02 Regeneron Pharmaceuticals, Inc. Anti-Staphylococcus antibodies and uses thereof
KR20220019755A (ko) 2019-06-11 2022-02-17 리제너론 파마슈티칼스 인코포레이티드 PcrV에 결합하는 항-PcrV 항체, 항-PcrV 항체를 포함하는 조성물, 및 이의 사용 방법
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN113444172A (zh) 2020-03-25 2021-09-28 兴盟生物医药(苏州)有限公司 金黄色葡萄球菌α-毒素特异性抗体及其应用
KR20230147616A (ko) * 2021-01-11 2023-10-23 스타맵 바이오로직스 (쑤저우) 씨오., 엘티디 황색포도상구균 α-독소를 표적으로 하는 항원 결합단백질 및 이의 응용
WO2022199527A1 (zh) * 2021-03-22 2022-09-29 星济生物(苏州)有限公司 靶向肺炎链球菌溶血素的抗原结合蛋白及其用途
WO2023208123A1 (zh) * 2022-04-28 2023-11-02 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体
CN115894674B (zh) * 2022-12-20 2023-07-25 厦门润康源生物科技有限公司 一种用于检测冠状病毒的抗体及制备方法和应用
CN116789814B (zh) * 2023-06-27 2024-03-29 重庆原伦生物科技有限公司 一种特异性结合金黄色葡萄球菌α-溶血素的抗体及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
GB8426463D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
JP2003503015A (ja) 1999-05-03 2003-01-28 メダレツクス・インコーポレーテツド スタフィロコッカス・アウレウスに対するヒト抗体
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
US20180221466A9 (en) 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
CN101466406B (zh) 2006-06-12 2012-06-27 葛兰素史密斯克蓝生物品公司 α-毒素在治疗和预防葡萄球菌感染上的用途
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2009029831A1 (en) 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
EP2644192B1 (en) 2007-09-28 2017-05-10 Pfizer Inc Cancer Cell Targeting Using Nanoparticles
EP2291196A4 (en) 2008-05-12 2012-05-30 Strox Biopharmaceuticals Llc FOR STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODY PREPARATIONS
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
EP3916011A1 (en) 2009-06-26 2021-12-01 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
WO2012031260A2 (en) 2010-09-02 2012-03-08 Excelimmune, Inc. Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof
SG10201600899PA (en) 2011-02-08 2016-03-30 Medimmune Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
US20140286960A1 (en) 2011-07-28 2014-09-25 Cangene Corporation Staphlococcus aureus alpha-hemolysin antibodies
WO2013093693A1 (en) * 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
EP2668208B1 (en) 2012-04-17 2015-06-03 ARSANIS Biosciences GmbH Cross-reactive staphylococcus aureus antibody
CN112316135A (zh) 2012-11-06 2021-02-05 米迪缪尼有限公司 治疗金黄色葡萄球菌相关疾病的方法
JP6473746B2 (ja) * 2013-10-17 2019-02-20 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 交差反応性黄色ブドウ球菌抗体配列
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TWI701258B (zh) * 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
AU2016249837A1 (en) 2015-04-17 2017-09-28 Arsanis Biosciences Gmbh Anti-staphylococcus aureus antibody combination preparation
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體

Also Published As

Publication number Publication date
CA3048989A1 (en) 2018-07-12
US20200016275A1 (en) 2020-01-16
KR20190101435A (ko) 2019-08-30
CO2019006902A2 (es) 2019-07-31
MA47202A (fr) 2019-11-13
US11571482B2 (en) 2023-02-07
AU2018206531A1 (en) 2019-07-25
US20210162059A1 (en) 2021-06-03
JP2020504759A (ja) 2020-02-13
TWI781130B (zh) 2022-10-21
AR110719A1 (es) 2019-04-24
CN110167960B (zh) 2023-01-13
US10463748B2 (en) 2019-11-05
TW201837054A (zh) 2018-10-16
WO2018128973A1 (en) 2018-07-12
US10940211B2 (en) 2021-03-09
CN110167960A (zh) 2019-08-23
MX2019007784A (es) 2019-09-06
US20180214569A1 (en) 2018-08-02
PH12019501425A1 (en) 2020-06-15
BR112019013375A2 (pt) 2020-02-11
CL2019001836A1 (es) 2019-10-04
EP3565835A1 (en) 2019-11-13
JP2023011710A (ja) 2023-01-24
IL267600A (en) 2019-08-29
TW202311284A (zh) 2023-03-16

Similar Documents

Publication Publication Date Title
EA201991643A1 (ru) Человеческие антитела к токсину гемолизину а s.aureus
EA201691877A1 (ru) Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
EA202090019A1 (ru) Спироциклические индолины в качестве модуляторов il-17
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
DOP2020000245A (es) Anticuerpos il-11
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201790377A1 (ru) Антитела к глюкагону и их применения
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201990778A1 (ru) Анти-il-33 антитела и их применение
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
TW201613575A (en) Treatment of polybacterial infections
EA201792006A1 (ru) Антимикробные соединения и способы их получения и их применение
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201992248A1 (ru) АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
BR112019005539A2 (pt) métodos de tratamento de lesão renal aguda
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37
BR112021025421A2 (pt) Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
EA201990988A1 (ru) Антитела против chikv и пути их применения
EA201892475A1 (ru) Оксабороловые сложные эфиры, их применение
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
EA202090260A1 (ru) Средства и способы для генотерапии aav у человека
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ